Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome: a prospective, open-label, and single-arm study

Table 9 Change in stool form score for each IBS subtype score (FAS)

IBS subtypes	Visit	N	Change in stool form score					95% CI of mean	Paired t-tests
IBS subtypes	Visit	N	Mean	SD	Minimum	Median	Maximum	95% CI of mean	Paired t-tests
IBS-C	Week 2	18	0.22	1.45	-1.7	0.05	4.5	-0.49, 0.94	p = 0.524
IBS-C	Week 4	18	0.09	0.85	-1.1	0.00	2.3	-0.33, 0.51	p = 0.662
IBS-D	Week 2	33	-0.39	0.65	-2.2	-0.30	0.9	-0.61, -0.16	p = 0.001
IBS-D	Week 4	33	-0.14	0.67	-1.7	-0.10	1.0	-0.38, 0.09	p = 0.233
IBS-M	Week 2	16	0.11	1.29	-1.6	0.05	2.7	-0.57, 0.79	p = 0.745
IBS-M	Week 4	16	0.04	1.23	-2.6	0.00	1.9	-0.61, 0.69	p = 0.904
Total	Week 2	67	-0.11	1.10	-2.2	-0.30	4.5	-0.37, 0.16	p = 0.431
Total	Week 4	67	-0.04	0.87	-2.6	0.00	2.3	-0.25, 0.17	p = 0.727

Amount of change in stool form score = “stool form score at 2, 4 weeks after treatment (or at the end of treatment)”– “stool form score at baseline”
SD standard deviation

ISSN: 1751-0759